Regeneron and Sanofi to present Praluent data at ACC 17

Regeneron and Sanofi are set to present new data from the Phase 3 Praluent (alirocumab) injection clinical trial program at this weekend’s American College of Cardiology Scientific Sessions (ACC 17) in Washington, D.C.
Praluent lowers low-density lipoprotein (LDL) cholesterol in patients by inhibiting the binding of proprotein convertase subtilisin/kexin type 9 (PCSK9) to the LDL receptor. In doing so, it makes more LDL receptors available on the surface of liver cells and reduces the levels of LDL cholesterol in the blood.
The drug is available in two dosages – 75mg and 150mg – and is the only PSCK9 inhibitor to give physicians the option of selecting dosage based on their patients’ needs.
At ACC. 17, Regeneron and Sanofi will give a series of presentations on Friday and Saturday discussing the most recent data from the clinical trial program’s Phase 3. These presentations will include the results of testing in several patient subsets, including patients with diabetes, patients with heterozygous familial hypercholesterolemia (HeFH) and patients with atherosclerotic cardiovascular disease.
The developers will also present post-hoc analyses on Praluent’s effect on major cardiovascular events and a safety update based on real-world data garnered from the open-label extension trial of Praluent.